Trial Profile
A Study to Evaluate the Efficacy and Safety of Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 May 2022
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Peanut hypersensitivity
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 19 Aug 2021 Status changed from active, no longer recruiting to completed.
- 09 Mar 2021 Planned End Date changed from 25 May 2021 to 27 May 2021.
- 09 Mar 2021 Status changed from recruiting to active, no longer recruiting.